What's Going On With BioVie Stock on Tuesday?
BioVie reported Phase 2 ADDRESS-LC trial results evaluating bezisterim for Long COVID, showing significant subgroup improvements.
Stocks · News reference
BioVie To Present Phase 2 Bezisterim Data In Long COVID, Parkinson’s At Neurology Conference October 18-19
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading